

# Novel Loss-of-Function PCSK9 Variant Is Associated with a French-Canadian Family and with Impaired Processing

Clinical Chemistry

57, 1415-1423

DOI: [10.1373/clinchem.2011.165191](https://doi.org/10.1373/clinchem.2011.165191)

Citation Report

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. <i>Clinical Lipidology</i> , 2012, 7, 621-640.                    | 0.4  | 16        |
| 2  | Loss- and Gain-of-function PCSK9 Variants. <i>Journal of Biological Chemistry</i> , 2012, 287, 33745-33755.   | 1.6  | 71        |
| 3  | Proprotein convertase subtilisin/kexin type 9 inhibition. <i>Current Opinion in Lipidology</i> , 2012, 23, 511-517.   | 1.2  | 38        |
| 4  | The PCSK9 decade. <i>Journal of Lipid Research</i> , 2012, 53, 2515-2524.   | 2.0  | 355       |
| 5  | My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. <i>Biochemistry and Cell Biology</i> , 2012, 90, 750-768.   | 0.9  | 18        |
| 6  | The biology and therapeutic targeting of the proprotein convertases. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 367-383.  | 21.5 | 647       |
| 7  | Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. <i>Lipids in Health and Disease</i> , 2013, 12, 70.                          | 1.2  | 50        |
| 8  | The genetic spectrum of familial hypercholesterolemia in Pakistan. <i>Clinica Chimica Acta</i> , 2013, 421, 219-225.  | 0.5  | 12        |
| 9  | Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions  |      |           |
| 10 | Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype. <i>Canadian Journal of Cardiology</i> , 2013, 29, 927-933.  | 0.8  | 32        |
| 11 | Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low-density Lipoprotein Cholesterol Lowering. <i>Pharmacotherapy</i> , 2013, 33, 447-460. | 1.2  | 5         |
| 12 | Structural and Functional Analysis of the CspB Protease Required for Clostridium Spore Germination. <i>PLoS Pathogens</i> , 2013, 9, e1003165.  | 2.1  | 99        |
| 13 | The promises of PCSK9 inhibition. <i>Current Opinion in Lipidology</i> , 2013, 24, 307-312.   | 1.2  | 17        |
| 14 | PCSK9 inhibitors. <i>Current Opinion in Lipidology</i> , 2013, 24, 251-258.   | 1.2  | 39        |
| 15 | The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1135.        | 2.0  | 40        |
| 16 | Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. <i>Isrn Endocrinology</i> , 2013, 1-8.          | 2.0  | 26        |
| 17 | The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions. <i>Journal of Biological Chemistry</i> , 2013, 288, 21473-21481.   | 1.6  | 151       |
| 18 | Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies. <i>Current Pharmaceutical Design</i> , 2013, 19, 3161-3172.                             | 0.9  | 70        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Assessing the functional consequence of loss of function variants using electronic medical record and large-scale genomics consortium efforts. <i>Frontiers in Genetics</i> , 2014, 5, 105.   | 1.1 | 3         |
| 20 | The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis. <i>Journal of Biological Chemistry</i> , 2014, 289, 29030-29043.  | 1.6 | 31        |
| 21 | Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor. <i>Archives of Biochemistry and Biophysics</i> , 2014, 545, 124-132.  | 1.4 | 14        |
| 22 | PCSK9 gene mutations and low-density lipoprotein cholesterol. <i>Clinica Chimica Acta</i> , 2014, 431, 148-153.   | 0.5 | 37        |
| 23 | PCSK9: From discovery to therapeutic applications. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 58-66.   | 0.7 | 83        |
| 24 | Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. <i>Current Atherosclerosis Reports</i> , 2014, 16, 439.  | 2.0 | 87        |
| 25 | Quercetin-3-O-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. <i>FEBS Open Bio</i> , 2014, 4, 755-762.     | 1.0 | 58        |
| 26 | Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 281-289. | 1.3 | 86        |
| 27 | PCSK9. <i>Circulation Research</i> , 2014, 114, 1022-1036.  | 2.0 | 495       |
| 28 | 17 $\beta$ -Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. <i>FEBS Journal</i> , 2015, 282, 2682-2696.   | 2.2 | 14        |
| 29 | Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1017-1024.   | 1.7 | 34        |
| 30 | Potential of PCSK9 as a new target for the management of LDL cholesterol. <i>Research Reports in Clinical Cardiology</i> , 0, , 73.   | 0.2 | 6         |
| 31 | LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): Design, synthesis and biochemical evaluation. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 890-907.   | 2.6 | 34        |
| 33 | Effects of lipoprotein apheresis on PCSK9 levels. <i>Atherosclerosis Supplements</i> , 2015, 18, 180-186.   | 1.2 | 20        |
| 34 | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. <i>Circulation</i> , 2015, 132, 1648-1666.  | 1.6 | 152       |
| 35 | PCSK9 and its modulation. <i>Clinica Chimica Acta</i> , 2015, 440, 79-86.   | 0.5 | 30        |
| 36 | PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.   |     | 44        |
| 37 | Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. <i>PLoS ONE</i> , 2016, 11, e0157230.   | 1.1 | 30        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 38 | PCSK9 Inhibitors. <i>Cardiology in Review</i> , 2016, 24, 141-152.   | 0.6 | 10        |
| 39 | 60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9). <i>Journal of Molecular Endocrinology</i> , 2016, 56, T49-T62.  | 1.1 | 43        |
| 40 | PCSK9 as a Biomarker of Cardiovascular Disease. , 2016, , 125-151.   |     | 1         |
| 41 | Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. <i>Protein Science</i> , 2016, 25, 2018-2027.   | 3.1 | 11        |
| 42 | Determination of cholesterol in blood. Part 3. <i>Review Journal of Chemistry</i> , 2016, 6, 252-329.  | 1.0 | 4         |
| 43 | Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction. <i>Lipids in Health and Disease</i> , 2016, 15, 193.   | 1.2 | 23        |
| 44 | Update on the molecular biology of dyslipidemias. <i>Clinica Chimica Acta</i> , 2016, 454, 143-185.  | 0.5 | 105       |
| 45 | PCSK9 as a therapeutic target for cardiovascular disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 810-814.  | 0.8 | 15        |
| 46 | Complexity of mechanisms among human proprotein convertase subtilisin/kexin type 9 variants. <i>Current Opinion in Lipidology</i> , 2017, 28, 161-169.   | 1.2 | 57        |
| 47 | Endoplasmic Reticulum Stress and Ca <sup>2+</sup> Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism. <i>Journal of Biological Chemistry</i> , 2017, 292, 1510-1523.  | 1.6 | 31        |
| 48 | Hypercholesterolemia: The role of PCSK9. <i>Archives of Biochemistry and Biophysics</i> , 2017, 625-626, 39-53.  | 1.4 | 45        |
| 49 | The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. <i>Pharmacological Reviews</i> , 2017, 69, 33-52.  | 7.1 | 90        |
| 50 | Comparing expression and activity of PCSK9 in SPRET/Eij and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol. <i>Molecular Genetics and Metabolism Reports</i> , 2017, 10, 11-17.  | 0.4 | 1         |
| 51 | The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3452-3460.   | 1.8 | 32        |
| 52 | PCSK9: Regulation and Target for Drug Development for Dyslipidemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 223-244.   | 4.2 | 58        |
| 53 | Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1700729. | 1.5 | 29        |
| 54 | The ever-expanding saga of the proprotein convertases and their roles in body homeostasis. <i>Current Opinion in Lipidology</i> , 2018, 29, 144-150.   | 1.2 | 30        |
| 55 | Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype. <i>Journal of Biological Chemistry</i> , 2018, 293, 1875-1886.   | 1.6 | 15        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 56 | Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1027-1038.                | 0.6 | 10        |
| 57 | Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. <i>Journal of Biological Chemistry</i> , 2018, 293, 7329-7343.  | 1.6 | 29        |
| 59 | Associations Between Soluble LDLR and Lipoproteins in a White Cohort and the Effect of PCSK9 Loss-of-Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3486-3495.   | 1.8 | 14        |
| 60 | PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1123-1132.   | 0.6 | 39        |
| 61 | Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. <i>Cardiovascular Research</i> , 2018, 114, 1595-1604.  | 1.8 | 9         |
| 62 | Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. <i>PLoS ONE</i> , 2018, 13, e0192850.   | 1.1 | 12        |
| 63 | Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.  | 1.8 | 63        |
| 64 | Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 9037-9047.  | 1.6 | 40        |
| 65 | Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 170-177.   | 1.3 | 18        |
| 66 | Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels “ experimental and clinical approaches with lipid-lowering agents. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 930-949.  | 0.8 | 64        |
| 67 | Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2019, 30, 428-437.   | 1.2 | 6         |
| 68 | Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 199. | 1.1 | 47        |
| 69 | Functional analysis of natural PCSK9 mutants in modern and archaic humans. <i>FEBS Journal</i> , 2020, 287, 515-528.   | 2.2 | 8         |
| 70 | PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis. <i>Frontiers in Genetics</i> , 2020, 11, 1020.  | 1.1 | 29        |
| 71 | Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. <i>Drug Safety</i> , 2020, 43, 567-582.  | 1.4 | 9         |
| 72 | Protease propeptide structures, mechanisms of activation, and functions. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2020, 55, 111-165.  | 2.3 | 37        |
| 73 | The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. <i>Journal of Clinical Investigation</i> , 2021, 131, .   | 3.9 | 29        |
| 74 | Current Evidence and Future Directions of PCSK9 Inhibition. <i>US Cardiology Review</i> , 0, 15, .   | 0.5 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 75 | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. International Journal of Cardiology, 2021, 335, 7-14. | 0.8 | 13        |
| 76 | The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis, 2021, 330, 52-60.  | 0.4 | 23        |
| 77 | PCSK9 as a Biomarker of Cardiovascular Disease. , 2015, , 1-27.  |     | 1         |
| 78 | Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. Journal of General Virology, 2018, 99, 44-61.  | 1.3 | 12        |
| 79 | PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation. PLoS ONE, 2013, 8, e72113.   | 1.1 | 20        |
| 80 | Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease. International Journal of Biomedical Investigation, 2018, 1, 1-18.  | 0.7 | 4         |
| 81 | Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9. International Journal of Biomedical Investigation, 2020, 3, 1-17.  | 0.7 | 5         |
| 82 | PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD). Advanced Pharmaceutical Bulletin, 2020, 10, 502-511.  | 0.6 | 15        |
| 83 | The Multifaceted Biology of PCSK9. Endocrine Reviews, 2022, 43, 558-582.   | 8.9 | 75        |
| 84 | Statins and PCSK9 Inhibitors: Defining the Correct Patients. , 2015, , 99-117.   |     | 1         |
| 85 | Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. Contemporary Cardiology, 2021, , 269-294.   | 0.0 | 0         |
| 86 | Shortcomings on genetic testing of Familial hypercholesterolemia (FH) in India: Can we collaborate to establish Indian FH registry?. Indian Heart Journal, 2022, 74, 1-6.  | 0.2 | 2         |
| 87 | The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. Metabolites, 2022, 12, 215.   | 1.3 | 10        |
| 88 | ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease. Neurobiology of Aging, 2022, 115, 20-28.  | 1.5 | 20        |
| 89 | The biological relevance of PCSK9: when less is better. Biochemistry and Cell Biology, 2022, 100, 189-198.   | 0.9 | 4         |
| 90 | Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity. Kidney360, 2022, 3, 1394-1410.   | 0.9 | 10        |
| 91 | Molecular and cellular biology of PCSK9: impact on glucose homeostasis. Journal of Drug Targeting, 2022, 30, 948-960.  | 2.1 | 8         |
| 92 | Inclisiran: How Widely and When Should We Use It?. Current Atherosclerosis Reports, 2022, 24, 803-811.   | 2.0 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 93  | Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond. <i>Current Atherosclerosis Reports</i> , 2022, 24, 821-830.                               | 2.0 | 29        |
| 94  | A multienzyme S-nitrosylation cascade regulates cholesterol homeostasis. <i>Cell Reports</i> , 2022, 41, 111538.   | 2.9 | 7         |
| 95  | PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. <i>Cells</i> , 2022, 11, 4132.   | 1.8 | 5         |
| 96  | PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, . | 3.5 | 8         |
| 101 | Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .       | 7.1 | 1         |